467 related articles for article (PubMed ID: 28244067)
1. WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.
Driehuis E; Clevers H
Br J Pharmacol; 2017 Dec; 174(24):4547-4563. PubMed ID: 28244067
[TBL] [Abstract][Full Text] [Related]
2. WNT signalling: mechanisms and therapeutic opportunities.
Schulte G; Bryja V
Br J Pharmacol; 2017 Dec; 174(24):4543-4546. PubMed ID: 29235106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors.
Zimmerli D; Hausmann G; Cantù C; Basler K
Br J Pharmacol; 2017 Dec; 174(24):4600-4610. PubMed ID: 28521071
[TBL] [Abstract][Full Text] [Related]
4. Molecular regulation and pharmacological targeting of the β-catenin destruction complex.
van Kappel EC; Maurice MM
Br J Pharmacol; 2017 Dec; 174(24):4575-4588. PubMed ID: 28634996
[TBL] [Abstract][Full Text] [Related]
5. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology.
Kagey MH; He X
Br J Pharmacol; 2017 Dec; 174(24):4637-4650. PubMed ID: 28574171
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy.
Lyou Y; Habowski AN; Chen GT; Waterman ML
Br J Pharmacol; 2017 Dec; 174(24):4589-4599. PubMed ID: 28752891
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
8. Assembly and architecture of the Wnt/β-catenin signalosome at the membrane.
DeBruine ZJ; Xu HE; Melcher K
Br J Pharmacol; 2017 Dec; 174(24):4564-4574. PubMed ID: 28941231
[TBL] [Abstract][Full Text] [Related]
9. Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers.
Flanagan DJ; Vincan E; Phesse TJ
Br J Pharmacol; 2017 Dec; 174(24):4666-4683. PubMed ID: 28568899
[TBL] [Abstract][Full Text] [Related]
10. Translation of WNT developmental programs into stem cell replacement strategies for the treatment of Parkinson's disease.
Toledo EM; Gyllborg D; Arenas E
Br J Pharmacol; 2017 Dec; 174(24):4716-4724. PubMed ID: 28547771
[TBL] [Abstract][Full Text] [Related]
11. The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy.
Kikuchi A; Fumoto K; Kimura H
Br J Pharmacol; 2017 Dec; 174(24):4651-4665. PubMed ID: 28514532
[TBL] [Abstract][Full Text] [Related]
12. Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.
Janovská P; Bryja V
Br J Pharmacol; 2017 Dec; 174(24):4701-4715. PubMed ID: 28703283
[TBL] [Abstract][Full Text] [Related]
13. 'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.
Ong MS; Cai W; Yuan Y; Leong HC; Tan TZ; Mohammad A; You ML; Arfuso F; Goh BC; Warrier S; Sethi G; Tolwinski NS; Lobie PE; Yap CT; Hooi SC; Huang RY; Kumar AP
Br J Pharmacol; 2017 Dec; 174(24):4684-4700. PubMed ID: 28736855
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
15. Wnt Signaling in Cancer: Not a Binary ON:OFF Switch.
Flanagan DJ; Vincan E; Phesse TJ
Cancer Res; 2019 Dec; 79(23):5901-5906. PubMed ID: 31431458
[TBL] [Abstract][Full Text] [Related]
16. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.
Serafino A; Sferrazza G; Colini Baldeschi A; Nicotera G; Andreola F; Pittaluga E; Pierimarchi P
Expert Opin Drug Discov; 2017 Feb; 12(2):169-186. PubMed ID: 27960558
[TBL] [Abstract][Full Text] [Related]
17. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
18. Can we safely target the WNT pathway?
Kahn M
Nat Rev Drug Discov; 2014 Jul; 13(7):513-32. PubMed ID: 24981364
[TBL] [Abstract][Full Text] [Related]
19. New insights into cardiotoxicity caused by chemotherapeutic agents.
Grieve DJ; Davidson SM
Br J Pharmacol; 2017 Nov; 174(21):3675-3676. PubMed ID: 29046013
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
